Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Med. Fee Curtailment Policy Caused Collapse of Med. Insurance System: 3 Social Insurance Unions
September 17, 2007
- Korosho to Shift Priority from Treatment of ADRs to Prevention
September 17, 2007
- TOPICS／JADEC, sanofi-aventis Hold HbA1c Awareness Promotion Campaign
September 17, 2007
- Use e-Details to Enhance QOV: Mr Takuma of CareNet
September 17, 2007
- Japan's First New-Type Influenza Vaccines Recommended for Approval
September 17, 2007
- SURVEY／Antirheumatic Drug Market Grew by 49% in 2006: Fuji Keizai Databook
September 17, 2007
- GENERICS NEWS IN BRIEF
September 17, 2007
- EFPIA Appreciates 20% Increase in Budget Request for Innovation
September 17, 2007
- Lundbeck, Takeda Tie Up to Develop Drugs for Mood and Anxiety Disorders
September 17, 2007
- CSL Behring Is Discriminated Against in Japan: President Mr Turner
September 17, 2007
- REGULATORY NEWS IN BRIEF
September 17, 2007
- SymBio Acquires Worldwide Rights to PEG-ZnPP
September 17, 2007
- POTELLIGENT the Most Important Technology Kyowa Hakko Has Developed in the Last 20 Years: Dr Shitara
September 17, 2007
- Korosho to Create "Healthcare Clusters" to Promote Drug Discovery
September 10, 2007
- Our Generics Had Economic Effects of \58.6 Bil. in 2006: Taiyo Yakuhin
September 10, 2007
- JMA Proposes Same Prices for Original Drugs and Generics
September 10, 2007
- Major Pharmas Tie Up with Generic Firms: Seminar
September 10, 2007
- REGULATORY NEWS IN BRIEF
September 10, 2007
- JGPRG to Designate Oct. as "Generic Drug Promotion Month"
September 10, 2007
- NBI to Go on Offensive in the Market for ARBs with 1,000 MRs
September 10, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…